Introduction {#S0001}
============

Skin and soft tissue infections (SSTIs) are common in both the outpatient and inpatient settings. *Staphylococcus aureus* is the most common causative pathogen of the SSTIs,[@CIT0001] particularly in purulent infections such as furuncles, carbuncles, cutaneous abscesses, and impetigo.

Community-associated methicillin-resistant *S. aureus* (CA-MRSA) has emerged as an important pathogen worldwide. The prevalence of CA-MRSA in SSTIs varies from region to region, 2.6% in China and 23% in the Middle East.[@CIT0002],[@CIT0003] In addition, the global distribution of CA-MRSA clones is heterogeneous and often characterized by a regional predominant clonal lineage.[@CIT0004] ST121 was previously the most common community-associated *Staphylococcus aureus* (CA-*S. aureus*) clone in SSTIs in China.[@CIT0002] The ST398 was then reported as the predominant clone in Jiangsu Province and Beijing, China.[@CIT0005],[@CIT0006] Since the dominant CA-MRSA clones are likely to have evolved from locally circulating community-associated methicillin-sensitive *S. aureus* (CA-MSSA) genotypes that are strongly associated with SSTIs,[@CIT0007],[@CIT0008] it is important to investigate the CA-*S. aureus* clonal structure within SSTIs around the local district.

Furthermore, virulence factors are highly associated with the pathogenesis of *S. aureus* invasive infections such as toxic shock syndrome and staphylococcal scalded skin syndrome (SSSS). Panton--Valentine leukocidin (PVL), for instance, is a key virulence factor. Previous studies have shown the association between PVL and severe invasive infections.[@CIT0009],[@CIT0010] Thus, it is important to characterize the virulence factors of CA-*S. aureus* for improving therapeutic approaches.

This study is focused on investigating purulent SSTIs cases in Beijing and characterizing *S. aureus* by multilocus sequence typing (MLST) types, SCCmec types, and key virulence factors. To our knowledge, it is the first study to report PVL+ ST22 CA-MSSA, an epidemic lineage in Europe,[@CIT0011] as a predominant clone in China.

Methods {#S0002}
=======

*Staphylococcus aureus* isolates {#S0002-S2001}
--------------------------------

From April 2015 to April 2017, pathogen detections were performed for all outpatients with purulent SSTIs in the department of dermatology in a hospital located in Beijing. The bacterial identification was performed by Matrix-Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry. All *S. aureus* clinical isolates were maintained with tryptic soy broth (TSB) at −70°C. And they were revived by streaking onto Columbia blood agar and cultured at 35°C overnight.

Antimicrobial susceptibility testing {#S0002-S2002}
------------------------------------

Antimicrobial susceptibility testing of *S. aureus* isolates was performed with a commercial VITEK Compact II system. Antibiotics susceptibility profiles were determined according to Clinical Laboratory Standards Institute Performance Standards of Antimicrobial Susceptible Testing (CLSI document M100 27th edition).

MLST and SCCmec genotype {#S0002-S2003}
------------------------

MLST analysis of *S. aureus* isolates was performed according to previously described procedures.[@CIT0012] In the MLST database (<https://pubmlst.org/saureus/>), the sequences of seven housekeeping genes (*arc*C, *aro*E, *glp*F, *gmk, pta, tpi*, and *yqi*) were compared to existing sequences by the assignment of allelic numbers. The SCC*mec* genotype was also identified as previously described.[@CIT0013]

Phylogenetic analysis {#S0002-S2004}
---------------------

ST22 clinical isolates were compared with two representatives of epidemic ST22 *S. aureus* strains, H-EMRSA-15 (NZ_CP007659.1:538355-539911) and HO 5096 0412 (HE681097.1:474448-476002), to construct phylogenetic tree for 16S rRNA gene using MEGA X software.[@CIT0014] 16S rRNA sequencing of clinical *S. aureus* isolates was carried out by a commercial company (Beijing Ruibiotech) using a primer pair, 27F 5-AGAGTTTGATCCTGGCTCAG and 1492R 5-TACGGCTACCTTGTTACGACTT.

Detection of virulence genes {#S0002-S2005}
----------------------------

All *S. aureus* isolates were screened for toxic shock syndrome toxin 1 gene (*tst-1*), Panton--Valentine leukocidin genes (*lukS/lukF*), three types of Staphylococcal exfoliative toxin (ET) genes (*etA, etB, etD*), epidermal cell differentiation inhibitor genes (*edinA* and *edinB*), and intracellular adhesion molecule genes (*icaA* and *icaD)* by PCR with appropriate primers as previously described.[@CIT0015]--[@CIT0022]

Biofilm formation assay {#S0002-S2006}
-----------------------

Biofilm formation contributes to the pathogenesis of *S. aureus*. Quantification of biofilms was performed using a modified Microtiter plate method.[@CIT0023] Briefly, the bacterial isolates were cultured in TSB and incubated at 37ºC overnight. The cultures were diluted with fresh TSB to 10^6^ CFU/mL. Two hundred microliters of the diluted solution was added to sterile 96-well plates and incubated at 37ºC for 24 hrs. The negative control wells contained TSB alone. After 24-hr incubation, broth was removed and the wells were gently washed three times with phosphate-buffered saline. After the wells were dried at room temperature, they were stained with 0.1% crystal violet. Then, the crystal violet bound to the biofilms in the wells was dissolved by 30% acetic acid. The optical density (OD) was measured at 570 nm by BioTek Synergy H1 reader. Each assay was performed in triplicate wells and was repeated three times. The cutoff of OD (ODc) was defined as three standard deviations above the mean OD of the negative control. The ability of biofilm formation was classified as follows: OD≤ODc, negative; ODc\<OD≤2xODc, weak; 2xODc\<OD≤4xODc, moderate; and 4xODc\<OD, strong.

Statistical analysis {#S0002-S2007}
--------------------

The correlation between the antibiotic resistance and biofilm formation was evaluated by the Pearson Chi-Square test. *P*-values less than 0.05 were regarded as significant. The statistic software used in our study was MedCalc 15.2.2 (Seoul, Korea).

Results {#S0003}
=======

*Staphylococcus aureus* isolates {#S0003-S2001}
--------------------------------

One hundred fifteen purulent SSTIs outpatients were enrolled in this study from April 2015 to April 2017. *S. aureus* was the most common pathogen, accounting for 38.3% (44/115). A total of 44 non-duplicate *S. aureus* isolates were recovered from abscess.

Molecular characteristics of CA-*S*. *aureus* {#S0003-S2002}
---------------------------------------------

Of 44 CA *S. aureus* strains, MSSA accounted for 79.6% (n=35), and MRSA for 20.4% (n=9). All CA-MRSA harbored SCC*mec* Ⅳ or Ⅴ. Eleven distinct sequence types (STs) were identified among the 44 isolates ([Table 1](#T0001){ref-type="table"}), among which the most prevalent ST22 accounted for 40.9% (n=18). Furthermore, the predominant ST among MSSA was ST22 (17/35, 48.6%), followed by ST398 (5/35, 14.3%), ST188 (4/35, 11.4%), ST121 (2/35, 5.7%), and ST5 (2/35, 5.7%) respectively. Meanwhile, the most prevalent ST within MRSA was the clonal complex 59 (CC59) including ST59 (5/9, 55.6%) and ST338 (2/9, 22.2%). Other clones were isolated sporadically.Table 1MLST typing, biofilm formation, and virulence factors genes of 44 *S. aureus* isolations from SSTI patientsNo.SexAge (years)PhenotypeSCCmec TypeMLSTBiofilm*lukS/lukFtst-1et*A*edin*A*icaAicaD*1F51MRSAⅣ338ModeratePPNNPP2F4MRSAⅤ338ModeratePPNNPP3M25MRSAⅤ59ModeratePPNNPP4F19MRSAⅤ59ModeratePPNNPP5F30MRSAⅤ59ModeratePPNNPP6F29MRSAⅣ59ModerateNPNNPP7F2MRSAⅤ59ModerateNPNNPP8M11MSSA59ModeratePPNNPP9F39MRSAⅣ7WeakNPNNPP10F50MSSA7WeakNPNNPP11M3MRSAⅣ22WeakPPNNPP12M34MSSA22WeakPPNNPP13F22MSSA22WeakPPNNPP14F29MSSA22WeakPPNNPP15M37MSSA22WeakPPNNPP16F34MSSA22WeakPPNNPP17F41MSSA22WeakPPNNPP18M26MSSA22WeakPPNNPP19M2MSSA22WeakNPNNPP20M11MSSA22WeakPPNNPP21M4MSSA22WeakNPNNPP22F46MSSA22ModeratePPNNPP23M9MSSA22WeakPPNNPP24F34MSSA22WeakNPNNPP25F29MSSA22WeakPPNNPP26M8MSSA22WeakPPNNPP27M22MSSA22WeakPPNNPP28F73MSSA22WeakPPNNPP29M33MSSA398WeakNPNNPP30M20MSSA398WeakNNNNPP31M23MSSA398ModerateNPNNPP32M29MSSA398ModerateNPNNPP33M59MSSA398WeakNPNNPP34M61MSSA188ModerateNPNNPP35M35MSSA188WeakNPNNPP36M27MSSA188WeakNPNNPP37M9MSSA188WeakNPNNPP38F3MSSA121WeakNNPPPP39M28MSSA121WeakNNPPPP40F28MSSA5ModerateNPNNPP41F85MSSA5WeakNPNNPP42M24MSSA88ModeratePPNNPP43F26MSSA6ModerateNPNNPP44M28MSSA1ModerateNPNNPP[^2]

Phylogenetic tree {#S0003-S2003}
-----------------

Neighbor-Joining tree for 16S rRNA gene of predominant ST22 *S. aureus* showed two clades ([Figure 1](#F0001){ref-type="fig"}). Five out of 18 (27.8%) ST22 isolates exhibit the same evolutionary origins as the epidemic ST22 EMRSA-15 (HO 5096 0412 and H-EMRSA-15) in Europe.Figure 1Neighbor-Joining tree of ST22 *S. aureus* isolates. The tree was rooted by the representative reference genomes of ST22 EMRSA-15 (HO 5096 0412 and H-EMRSA-15). The optimal tree with the sum of branch length =0.00212286 is shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the Maximum Composite Likelihood method and are in the units of the number of base substitutions per site. Evolutionary analyses were conducted in MEGA X.

Virulence genes {#S0003-S2004}
---------------

The prevalence of PVL positive *S. aureus* was 50% (22/44), and there was no significant difference (*p*=0.45) between MRSA (66.7%, 6/9) and MSSA (45.7%, 16/35). 83.3% (15/18) of ST22 was detected positive for *lukS/lukF*. All ST398, ST188, ST121, and ST5 isolates did not carry the *lukS/lukF* genes. Forty-one isolates, except two ST121 and one ST398, carried the *tst-1* gene accounting for 93.2% (38/41). Only ST121 isolates carried *et*A and *edin*A, accounting for 4.5%. However, none were found positive for *et*B, *et*D, and *edin*B. All of the isolates possessed two genes i*ca*A and i*ca*D coding for critical intracellular adhesion molecules.

Biofilm formation {#S0003-S2005}
-----------------

The results showed that 74.3% (26/35) of isolates were weak biofilm producers, and 25.7% (9/35) MSSA isolates were moderate biofilm producers, while 77.8% (7/9) MRSA were moderate biofilm producers ([Table 2](#T0002){ref-type="table"}). All CC59 isolates, including ST59 and ST338, exhibit moderate biofilm formation ability, irrespective of methicillin susceptibility.Table 2Biofilm formation ability of MSSA and MRSABiofilm formationMSSAMRSANumberPercentNumberPercentModerate925.7777.8Weak2674.3222.2

Comparison of susceptibility profiles of different biofilm producers {#S0003-S2006}
--------------------------------------------------------------------

Antibiotics sensitivity was different between weak and moderate biofilm producers among MSSA subgroup. Within the MSSA subgroup, the sensitivity to benzylpenicillin, gentamycin, ciprofloxacin, levofloxacin, and erythromycin of weak biofilm-producing isolates were higher than that of moderate biofilm producers; however, the differences were not statistically significant. The only significant difference of antibiotic sensitivity was observed in sulfamethoxazole/trimethoprim (92.3% vs 55.6%, *p*=0.03) ([Table 3](#T0003){ref-type="table"}). Although MRSA subgroup consisted of only nine isolates, the majority of them are moderate biofilm producers. All MRSA and MSSA isolates were sensitive to vancomycin, rifampicin, linezolid, moxifloxacin, and tigecycline.Table 3The sensitivities of antibiotics between weak biofilm and moderate biofilm producers among MSSA subgroupAntibioticsWeak biofilm (%) (N=26)Moderate biofilm (%) (N=9)*p*Benzylpenicillin15.411.10.62Clindamycin46.222.30.19Erythromycin42.333.30.47Sulfamethoxazole/trimethoprim92.355.60.03\*Gentamycin92.366.70.1Ciprofloxacin92.377.80.27Levofloxacin96.1577.80.16Rifampicin1001001Linezolid1001001Moxifloxacin1001001Vancomycin1001001Tetracycline1001001Tigecycline1001001

Discussion {#S0004}
==========

In the present research, we determined the clonal distribution, virulence factors, and biofilm formation ability of *S. aureus* clinical isolates from purulent SSTIs. Several findings were reported. Firstly, an endemic PVL^+^ ST22 clone similar to EMRSA-15 appeared in this region. Secondly, CA-MRSA accounted for 20.4% of SSTIs. The local circulating MRSA clone belongs to CC59, and all CC59 isolates have stronger biofilm formation ability compared to ST22. Finally, the majority of isolates harbored *tst-1* and *lukS/lukF* genes.

It is worth noting that we screened a dominant clone PVL^+^ ST22 CA-MSSA circulating in this Beijing community, whereas previous study[@CIT0006] suggested the PVL^+^ ST398 was the most dominant clone among CA-MSSA with SSTIs around Beijing. It is likely that ST22 has replaced ST398 as the dominant lineage in Beijing. This trend deserves attention from the physicians for the following reasons. Firstly, ST22 clone has a strong ability to spread. ST22-IVh (EMRSA-15 clone) is a pandemic lineage originated from Europe, which spread rapidly through hospitals following introduction into Singapore, replacing the endemic ST239 population.[@CIT0024],[@CIT0025] Recent studies reported several outbreaks of ST22 CA-MSSA or CA-MRSA.[@CIT0011],[@CIT0026],[@CIT0027] In our study, the phylogeny analysis indicated local PVL^+^ ST22 CA-MSSA is similar to epidemic EMRSA-15, which could serve as a reservoir for CA-MRSA. Secondly, ST22 clone is highly virulent. DeLencastre et al,[@CIT0028] document that ST22-IV effectively invade cells in vitro and is highly pathogenic in vivo compared with ST228-I. In addition, a long-term familial infection cluster was caused by a novel PVL-positive ST22 CA-MRSA in Japan.[@CIT0029]

The spread of CA-MRSA has become a serious problem worldwide. Our data showed the prevalence of CA-MRSA was 20.4%, which is much higher than previously reported \~4% in China.[@CIT0006] The prevalence of CA-MRSA was found dramatically increasing in a majority of regions.[@CIT0002],[@CIT0005],[@CIT0006],[@CIT0030] The trend would pose a serious challenge to local infection control.

As far as the clonal distribution of CA-MRSA is concerned, five CA-MRSA clones, ST1, ST30, ST80, ST59, and ST8, account for the vast majority of CA-MRSA infections worldwide.[@CIT0031] Different clonal lineages spread in specific regions, for instance, ST8 in Germany[@CIT0032] and ST59 in Taiwan.[@CIT0033] Several surveillance reports suggested that the predominant clone would shift across regions. A multicenter study in China between 2009 and 2011 revealed that the most prevalent sequence type was ST121 (19/51, 37.3%) among CA-MRSA with SSTIs,[@CIT0002] however, ST59 was found to be the most prevalent ST in China since 2012.[@CIT0034]--[@CIT0036] We also found the circulating clone CC59 accounted for 77.8% CA-MRSA. Indeed, ST59 CA-MRSA has become a persistent pandemic clone causing invasive infections around China now.[@CIT0036]

PVL is a key virulence factor of *S. aureus*, mainly associated with necrotic lesions in the skin or mucosa.[@CIT0018] The prevalence of *lukS/lukF* ranged from over 20% to approximately 80% of *S. aureus* isolates.[@CIT0006],[@CIT0030],[@CIT0034],[@CIT0037],[@CIT0038] We detected 50% of *S. aureus* harboring *lukS/lukF*. Particularly, 83.3% of ST22 isolates were PVL positive. Chen[@CIT0039] reported that ST22 tends to harbor a *lukS/lukF* gene compared to other ST types in China. Surprisingly, Gu[@CIT0005] detected no *lukS/lukF* gene among CA-MRSA with SSTIs in Jiangsu Province, China. So far, it is unknown whether PVL^+^ CA-MRSA clones arose through acquisition of the mec element from strains with a PVL^+^ MSSA or conversely, through acquisition of PVL phage by strains with a methicillin resistance background. Overall, we are concerned whether the PVL^+^ ST22 CA-MSSA clone would arise to become the dominant CA-MRSA clone around the city. Further studies are needed to uncover the possible evolution of the dominant PVL^+^ ST22 CA-MSSA over time in China.

TSST-1-producing *S. aureus* are more likely to cause complicated infections. In this study, we found the *tst-1* gene was detected among 93.2% CA-*S.aureus* isolates. The overall prevalence of *tst-1* carrying *S. aureus* in Iran was 21.3%, ranging from 0% to 68%.[@CIT0040] Moreover, a recent survey in China[@CIT0041] reported that only 3.9% MRSA strains harbored the *tst-1* gene. Concerning the *tst-1* gene, the prevalence is much higher in our study, so we presume high virulence isolates circulate around this community in Beijing.

ETs are the sole virulence factors responsible for SSSS, a disease mostly affecting neonates and children under 5 years of age. In Italy, *etA* positive ST5 clone *S. aureus* had ever caused an outbreak of skin infections in neonates.[@CIT0042] We found two ST121 clone strains contain both the *etA* gene and the *edinA* gene associated with epidermal hyperplasia. Yet, the *etA* gene positive *S. aureus* strains were rarely reported in China.[@CIT0034] Continuous monitoring ETs positive *S. aureus* in this community may be of interest.

Biofilm formation is another primary virulence factor of *S. aureus*.[@CIT0043] Different strains possess different adhesins and differ in their ability to produce biofilms. In this study, the majority of ST22 clones had poor biofilm formation ability, whereas all CC59 strains can produce robust biofilms. CA-MRSA isolates have stronger biofilm formation ability than CA-MSSA, 77.8% vs 25.7%. Therefore, the biofilm formation ability is likely related to the genetic background or the clonal types. In fact, it is necessary to validate the hypothesis with a larger size of samples. The intracellular adhesion molecules are the main mechanism of biofilm formation. All of the isolates harbored the *ica*A and i*ca*D genes in our study, which implies poor biofilm producers of ST22 would have potential to become strong biofilm producers. The bacterial biofilm communities are surrounded by exopolysaccharides matrix.[@CIT0044] Within this environment, bacteria develop polymicrobial interactions[@CIT0045] and increase antibiotics resistance.[@CIT0046] And some researchers reported a variable biofilm-producing ability of different MRSA isolates.[@CIT0047] According to our analysis, the moderate biofilm producers had a significantly lower sensitivity to Sulfamethoxazole/Trimethoprim. In addition moderate biofilm producers also exhibited lower, although not significantly, sensitivities against several other antibiotics including benzylpenicillin, gentamycin, ciprofloxacin, levofloxacin, and erythromycin. Furthermore, there were no differences in the sensitivities to many other antibiotics including rifampicin, linezolid, moxifloxacin, vancomycin, tetracycline, and tigecycline between different biofilm producers.

Conclusion {#S0005}
==========

In summary, we documented a prevalent community epidemic PVL^+^ ST22 CA-MSSA which had previously described as a sporadic clone in Beijing, China.[@CIT0006] The changing epidemiology of CA-*S. aureus* necessitates further surveillance to inform mechanisms of evolution, empiric treatment guidelines, and prevention strategies.
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